Screener
Assembly Biosciences ASMB Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Assembly Biosciences in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Assembly Biosciences’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211987
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Stockholders' equity | ||
| Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding | — | — |
| Common stock, $0.001 par value; 150,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 15,892,353 and 15,855,329 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 16 | 16 |
| Additional paid-in capital | 1,040,088 | 1,038,823 |
| Accumulated other comprehensive loss | (368) | (41) |
| Accumulated deficit | (841,126) | (832,047) |
| Total stockholders' equity | 198,610 | 206,751 |
| Total liabilities and stockholders' equity | $235,508 | $257,590 |
Item 1. Financial Statements
FAQ
- What is Assembly Biosciences's total equity?
- Assembly Biosciences (ASMB) reported total equity of $198.61M in Q1 2026.
- How has Assembly Biosciences's total equity changed year-over-year?
- Assembly Biosciences's total equity increased by 632.0% year-over-year, from $27.13M to $198.61M.
- What is the long-term trend for Assembly Biosciences's total equity?
- Over 5 years (2020 to 2025), Assembly Biosciences's total equity has grown at a -3.0% compound annual growth rate (CAGR), from $240.58M to $206.75M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Assembly Biosciences's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude